Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market

Reuters

2025/05/21

Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market

Uni-Bio Science Group Ltd. has announced that the marketing application for its Diquafosol Sodium Eye Drops, branded as 金因康®, has received official approval from the China National Medical Products Administration (NMPA). This approval marks a significant step for the company in addressing the growing market for dry eye syndrome treatments in China, which currently affects approximately 360 million patients. The market size is expected to exceed RMB42 billion by 2030, with a compound annual growth rate of 28.4%. The eye drops, designed to improve tear secretion and address corneal epithelial damage, aim to provide a solution for patients with dry eye syndrome accompanied by abnormal tear-associated corneal epithelial defects. The product is also projected to be among the first Blow-Fill-Seal $(BFS)$ Diquafosol products approved for listing, employing advanced technology for enhanced pharmaceutical quality. The company has expanded its sales channels and established strategic partnerships with API suppliers to ensure cost-effective production and distribution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537816189"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537816189\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537816189?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-21 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537816189","market":"us","top_or_hot":-1,"title":"Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Uni-Bio Science Group Ltd. has announced that the marketing application for its Diquafosol Sodium Eye Drops, branded as 金因康®, has received official approval from the China National Medical Products Administration (NMPA). This approval marks a significant step for the company in addressing the growing market for dry eye syndrome treatments in China, which currently affects approximately 360 million patients. The market size is expected to exceed RMB42 billion by 2030, with a compound annual growth rate of 28.4%. The eye drops, designed to improve tear secretion and address corneal epithelial damage, aim to provide a solution for patients with dry eye syndrome accompanied by abnormal tear-associated corneal epithelial defects. The product is also projected to be among the first Blow-Fill-Seal <a href=\"https://laohu8.com/S/BFS\">$(BFS)$</a> Diquafosol products approved for listing, employing advanced technology for enhanced pharmaceutical quality. The company has expanded its sales channels and established strategic partnerships with API suppliers to ensure cost-effective production and distribution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Uni-Bio Science Group Ltd. has announced that the marketing application for its Diquafosol Sodium Eye Drops, branded as 金因康®, has received official approval from the China National Medical Products Administration (NMPA). This approval marks a significant step for the company in addressing the growing market for dry eye syndrome treatments in China, which currently affects approximately 360 million patients. The market size is expected to exceed RMB42 billion by 2030, with a compound annual growth rate of 28.4%. The eye drops, designed to improve tear secretion and address corneal epithelial damage, aim to provide a solution for patients with dry eye syndrome accompanied by abnormal tear-associated corneal epithelial defects. The product is also projected to be among the first Blow-Fill-Seal <a href=\"https://laohu8.com/S/BFS\">$(BFS)$</a> Diquafosol products approved for listing, employing advanced technology for enhanced pharmaceutical quality. The company has expanded its sales channels and established strategic partnerships with API suppliers to ensure cost-effective production and distribution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL7KYFq2:1","article_id":"2537816189","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537816189","pubTimestamp":1747822849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Uni-Bio Science Group Ltd. has announced that the marketing application for its Diquafosol Sodium Eye Drops, branded as 金因康, has received official approval from the China National Medical Products Administration . This approval marks a significant step for the company in addressing the growing market for dry eye syndrome treatments in China, which currently affects approximately 360 million patients. The market size is expected to exceed RMB42 billion by 2030, with a compound annual growth rate of 28.4%. The eye drops, designed to improve tear secretion and address corneal epithelial damage, aim to provide a solution for patients with dry eye syndrome accompanied by abnormal tear-associated corneal epithelial defects. The product is also projected to be among the first Blow-Fill-Seal  Diquafosol products approved for listing, employing advanced technology for enhanced pharmaceutical quality. The company has expanded its sales channels and established strategic partnerships with API sup","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","00690":"联康生物科技集团"},"translate_title":"Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00690":0.9},"content_text":"Uni-Bio Science Group Announces Approval of Diquafosol Sodium Eye Drops by China NMPA, Targets Expanding Dry Eye Market\n    \n\n        Uni-Bio Science Group Ltd. has announced that the marketing application for its Diquafosol Sodium Eye Drops, branded as 金因康®, has received official approval from the China National Medical Products Administration (NMPA). This approval marks a significant step for the company in addressing the growing market for dry eye syndrome treatments in China, which currently affects approximately 360 million patients. The market size is expected to exceed RMB42 billion by 2030, with a compound annual growth rate of 28.4%. The eye drops, designed to improve tear secretion and address corneal epithelial damage, aim to provide a solution for patients with dry eye syndrome accompanied by abnormal tear-associated corneal epithelial defects. The product is also projected to be among the first Blow-Fill-Seal $(BFS)$ Diquafosol products approved for listing, employing advanced technology for enhanced pharmaceutical quality. The company has expanded its sales channels and established strategic partnerships with API suppliers to ensure cost-effective production and distribution.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}